ArticleCureus2025
A Case Series and Review of Hydroxychloroquine Toxicity and Monitoring: How Do We Dose Hydroxychloroquine?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quadrant-Specific Retinal Nerve Fiber Layer Thinning in Hydroxychloroquine Retinal Toxicity: A Controlled OCT-Based Structural and Exposure Analysis in Systemic Lupus Erythematosus.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxychloroquine (HCQ) is an anti-malarial drug safely used in rheumatologic conditions with its various mechanisms on immunomodulation aside from its impact on cardiovascular health. However, multiple systemic effects, from ocular toxicity to cardiotoxicity, were reviewed and reported within adequate weight-based HCQ doses, challenging the need for alternate HCQ monitoring. We report cases with catastrophic adverse events from chronic HCQ use and supratherapeutic blood HCQ levels while within the recommended weight-based dosing. Cases of supratherapeutic HCQ blood levels have emerged despite adherence to weight-based dosing, indicating the necessity for individualized monitoring. This study aims to highlight the toxicities associated with chronic HCQ use along with the limitations of current weight-based dosing guidelines. This also provides a discussion on the unique pharmacokinetics and pharmacodynamics of HCQ in better understanding proposed HCQ blood level monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.